Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Caribou Biosciences stock
Learn how to easily invest in Caribou Biosciences stock.
Caribou Biosciences Inc is a biotechnology business based in the US. Caribou Biosciences shares (CRBU) are listed on the NASDAQ and all prices are listed in US Dollars.
How to buy shares in Caribou Biosciences
- Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – CRBU – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Caribou Biosciences stock price (NASDAQ: CRBU)Use our graph to track the performance of CRBU stocks over time.
Caribou Biosciences shares at a glance
|Latest market close||$10.74|
|52-week range||$10.52 - $32.65|
|50-day moving average||$17.19|
|200-day moving average||$20.92|
|Wall St. target price||$31.20|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-3.37|
Buy Caribou Biosciences shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Caribou Biosciences stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Caribou Biosciences price performance over time
|1 week (2022-01-14)||-7.49%|
|1 month (2021-12-21)||-32.07%|
|3 months (2021-10-21)||-46.78%|
|6 months (2021-07-17)||N/A|
|1 year (2021-01-17)||N/A|
|2 years (2020-01-17)||N/A|
|3 years (2019-01-17)||N/A|
|5 years (2017-01-17)||N/A|
Caribou Biosciences financials
|Revenue TTM||$8 million|
|Gross profit TTM||$-22,064,000|
|Return on assets TTM||0%|
|Return on equity TTM||0%|
|Market capitalisation||$654.3 million|
TTM: trailing 12 months
Caribou Biosciences share dividends
We're not expecting Caribou Biosciences to pay a dividend over the next 12 months.
Caribou Biosciences overview
Caribou Biosciences, Inc. , a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma; and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for the treatment of relapsed or refractory multiple myeloma. The company also develops CB-012, an allogeneic anti-CD371 CAR-T cell therapy for the treatment of relapsed or refractory acute myeloid leukemia; and CB-020, an allogeneic CAR-NK cell therapy for the treatment of solid tumors. Caribou Biosciences has collaboration with AbbVie Manufacturing Management Unlimited Company to develop CAR-T cell therapies. The company was incorporated in 2011 and is headquartered in Berkeley, California. .
Caribou Biosciences in the news
Netflix quietly admits streaming competition is eating into growth
CARIBOU BIOSCIENCES, INC. : Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial Statements and Exhibits (form 8-K)
Caribou Biosciences Appoints Syed Rizvi, M.D., as Chief Medical Officer
Frequently asked questionsWhat percentage of Caribou Biosciences is owned by insiders or institutions?
Currently 9.703% of Caribou Biosciences shares are held by insiders and 51.005% by institutions. When does the fiscal year end for Caribou Biosciences?
Caribou Biosciences's fiscal year ends in December. Where is Caribou Biosciences based?
Caribou Biosciences's address is: 2929 7th Street, Berkeley, CA, United States, 94710 What is Caribou Biosciences's ISIN number?
Caribou Biosciences's international securities identification number is: US1420381089
More guides on Finder
Can Turo’s IPO do better than Uber and Airbnb?
Car-sharing service Turo has filed plans for an IPO. What you need to know.
Monie savings review
Monie offers 5% APY on deposits, but funds aren’t insured and the interface is buggy.
Covid test stocks
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Is Berkshire Hathaway the next $1 trillion stock?
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Tesla roars into 2022 after December drop
Record vehicle deliveries cause the Tesla stock price to move close to all-time highs.
How to buy Affinia Therapeutics (AFTX) stock when it goes public
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
How to buy Austin Gold (AUST) stock when it goes public
Everything we know about the Austin Gold IPO, plus information on how to buy in.
How to buy VinFast stock when it goes public
Everything we know about the VinFast IPO, plus information on how to buy in.
How to buy Nexalin Technology (NXL) stock when it goes public
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
How to buy Specialty Building Products (SBP) stock when it goes public
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Ask an Expert